By Yuhiro Sakakibara, Pharmacist and Head Manager of the Diagnostic Kit Section, TANAKA PRECIOUS METAL TECHNOLOGIES
A rapid diagnostic test is a remarkable piece of engineering. A small sample, a few minutes of waiting, and a coloured line can offer an important clue about what is happening inside the body.
For Southeast Asia, where dengue remains a persistent public health challenge and respiratory infections continue to drive demand for accessible testing, the science behind these results has real significance. The reliability of a rapid test depends not only on its biological detection method, but also on the quality of its materials and the precision of its manufacturing.
Small particles, significant potential
Colloidal gold has long been valued for its distinctive physical properties, and it also plays an important role in many of these tests, producing the visible signals that make rapid results possible. At the nanoscale, those properties become particularly useful. Gold nanoparticles interact with light in ways that produce a strong, characteristic colour, making them well suited to the lateral-flow tests familiar to many of us.
The principle is elegant. As a sample moves along a porous strip, it encounters biological reagents designed to recognise a particular target. In many antigen-based tests, antibodies attached to gold nanoparticles bind to the target of interest. Further along the strip, these complexes are captured at a designated test line, where the accumulated particles produce a visible signal.
No elaborate instrument is necessarily required. The result can be read with the naked eye.
This is made possible in part by a phenomenon known as localised surface plasmon resonance, which describes how the nanoparticles interact with incoming light. Their optical behaviour, combined with the ability to modify their surfaces to attach biological molecules such as antibodies, makes gold a valuable material for diagnostic applications. TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., for example, works with colloidal gold and protein immobilisation for diagnostic applications, thereby harnessing it for practical diagnostic testing.
The appeal is clear: sophisticated science, translated into a format that can be used far beyond a conventional laboratory.
But an elegant principle is only the beginning.
Reliability is built long before the line appears
A test can have a clever design and still disappoint if its materials are inconsistent. With gold nanoparticles, characteristics such as particle size, shape, surface chemistry and dispersion can influence the strength and consistency of the signal. If particles aggregate, for instance, their optical properties can change, and if antibodies do not attach appropriately, their ability to recognise the intended target may be compromised.
These are not minor details to be left to the laboratory, but fundamental for turning a promising detection method into a dependable product. A reliable diagnostic test does not simply come into being out of thin air. Manufacturers have to ensure that nanoparticles work as expected alongside membranes, buffers, antibodies as well as other components, and to reproduce this across batches.
For manufacturers, maintaining this consistency requires careful control over materials and production processes. TANAKA, for instance, demonstrated this in February 2026 by expanding its in-house diagnostic test-kit manufacturing capabilities to cover extraction-buffer dispensing and packaging, bringing more stages of production under one system to support quality control and supply reliability supported by an ISO 13485-based quality management system.
Southeast Asia’s diagnostic opportunity
Why does this matter particularly in Southeast Asia? Because diagnostic technology has to work in the context for which it is intended, not simply under ideal laboratory conditions.
Dengue remains a significant concern across the region, making appropriate clinical assessment and timely testing hugely important. Rapid tests can support clinical decision-making, although accuracy depends on the test, the specimen and the stage of infection.
Respiratory infections, including influenza and COVID-19, present another set of diagnostic needs. Different tests identify different biological targets, and a negative result does not always exclude infection.
The broader point is that accessibility alone is not enough. A test must also be appropriate for its intended use, perform consistently and communicate results that healthcare professionals can interpret responsibly. These demands place the quality of materials and manufacturing firmly within the wider discussion about diagnostic access.
For the region’s healthcare systems and manufacturers, the opportunity is not merely to produce tests faster or at greater volume. It is to build confidence in the products reaching healthcare providers and patients.
Looking beyond the visible result
There is a tendency to judge a rapid test by what is visible, such as the strip, the waiting time and the line that eventually appears. Yet much of its value is determined earlier, through decisions about materials, biological reagents, process controls and product validation.
Gold nanoparticles are a compelling example of how a seemingly small component can influence a much larger system. Their optical properties make rapid visual detection possible, but consistent performance depends on how well the entire test is designed and manufactured.
For Southeast Asia, where accessible diagnostics remain important to managing infectious diseases, that is a worthwhile perspective to bring into sharper focus.
The next advance in rapid testing may come from a new detection method, a more sensitive assay or a better-designed device. Whatever form it takes, the same principle will apply: innovation only delivers its full value when it can be translated into reliable performance, consistently and at scale.
The coloured line may be the result everyone sees. The real achievement is everything that makes it worth trusting.
